|
|
Vaccine Detail
|
Ad5-nCoV |
| Vaccine Information |
- Vaccine Name: Ad5-nCoV
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Tradename: Convidecia, PakVak
- Manufacturer: CanSino Biologics
- Vaccine Ontology ID: VO_0005144
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: SARS-CoV-2 spike protein (Zhu et al., 2020)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccination Protocol: Patients were immunized with 5 × 10e10 viral particles per 0·5 mL (low dose), 1 × 10e11 viral particles per mL (middle dose), or 1.5 × 10e11 viral particles per 1·5 mL (high dose). (Zhu et al., 2020)
- Immune Response: Anti-RBD antibodies detected at day 14. NAb titers peaked at day 28. TNF-α levels from CD8+ cells were highest in the high dose group. IFN-γ, IL-2 and TNF-α were detected in all groups. (Zhu et al., 2020)
|
| References |
Zhu et al., 2020: Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England). 2020; 395(10240); 1845-1854. [PubMed: 32450106].
|
|
